Literature DB >> 11283098

Comparison of Roche MONITOR and Organon Teknika NucliSens assays to quantify human immunodeficiency virus type 1 RNA in cerebrospinal fluid.

P Spearman1, S A Fiscus, R M Smith, R Shepard, B Johnson, J Nicotera, V L Harris, L A Clough, J McKinsey, D W Haas.   

Abstract

We compared Roche MONITOR and Organon Teknika NucliSens assays for human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid (CSF). Results of 282 assays were highly correlated (r = 0.826), with MONITOR values being 0.29 +/- 0.4 log(10) copies/ml (mean +/- standard deviation) values. Both assays can reliably quantify HIV-1 RNA in CSF.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11283098      PMCID： PMC87981          DOI： 10.1128/JCM.39.4.1612-1614.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

Review 1.  HIV-1-related central nervous system diseases.

Authors:  M Tardieu
Journal:  Curr Opin Neurol       Date:  1999-08       Impact factor: 5.710

Review 2.  NASBA: a novel, isothermal detection technology for qualitative and quantitative HIV-1 RNA measurements.

Authors:  J W Romano; B van Gemen; T Kievits
Journal:  Clin Lab Med       Date:  1996-03       Impact factor: 1.935

3.  Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments.

Authors:  R N Shepard; J Schock; K Robertson; D C Shugars; J Dyer; P Vernazza; C Hall; M S Cohen; S A Fiscus
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study.

Authors:  P Bürgisser; P Vernazza; M Flepp; J Böni; Z Tomasik; U Hummel; G Pantaleo; J Schüpbach
Journal:  J Acquir Immune Defic Syndr       Date:  2000-02-01       Impact factor: 3.731

5.  Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.

Authors:  D W Haas; L A Clough; B W Johnson; V L Harris; P Spearman; G R Wilkinson; C V Fletcher; S Fiscus; S Raffanti; R Donlon; J McKinsey; J Nicotera; D Schmidt; R E Shoup; R E Kates; R M Lloyd; B Larder
Journal:  AIDS Res Hum Retroviruses       Date:  2000-10-10       Impact factor: 2.205

6.  Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes.

Authors:  A Holguín; C de Mendoza; V Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-04       Impact factor: 3.267

7.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; K Hsia; S A Spector; J A Nelson; R K Heaton; M R Wallace; I Abramson; J H Atkinson; I Grant; J A McCutchan
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

8.  Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  J Coste; B Montes; J Reynes; M Peeters; C Segarra; J P Vendrell; E Delaporte; M Segondy
Journal:  J Med Virol       Date:  1996-12       Impact factor: 2.327

9.  Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture.

Authors:  J R Dyer; B L Gilliam; J J Eron; L Grosso; M S Cohen; S A Fiscus
Journal:  J Virol Methods       Date:  1996-07       Impact factor: 2.014

10.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910
View more
  1 in total

1.  Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.

Authors:  Paulo P Christo; Dirceu B Greco; Agdemir W Aleixo; Jose A Livramento
Journal:  BMC Infect Dis       Date:  2007-12-21       Impact factor: 3.090
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.